[Clinical deterioration of 4 of 5 cases of Cushing's syndrome after administration of STC 407].
D015068:17-Ketosteroids / Q000652:urine; D000305:Adrenal Cortex Hormones / Q000652:urine; D000328:Adult; D050260:Carbohydrate Metabolism; D003480:Cushing Syndrome / Q000188:drug therapy*; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced
D015068:17-Ketosteroids; D000305:Adrenal Cortex Hormones; D005938:Glucocorticoids
Klinische Verschlecterung bei 4 von 5 Fällen mit Cushing-Syndrom unter STC 407-Therapie.